|
|
| Breast cancer Trials | ||
| Study | Objective | Contact |
| SOFT trial: A Phase III Trial Evaluating the Role of Ovarian Function Suppression & the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer | Study of exemestane and ovarian function suppression in premenopausal women with hormone-responsive breast cancer | Principal Investigator: Corrine Zarwan, MD For more information contact Kori D. Hesse, study coordinator, at (781) 744-3071 |
| NSABP B39: A Randomized Phase III Study of Conventional Whole Breast Irradiation vs. Partial Breast Irradiation for Women with Stage 0, I or II Breast Cancer | A study comparing radiation to the entire breast to radiation to only part of the breast | Principal Investigator: Lyubov Girshovich, MD For more information contact Kori D. Hesse, study coordinator, at (781) 744-3071 |
| NSABP B42: A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in patients completing Five Years of Hormonal Therapy with Aromatase Inhibitor or Tamoxifen Followed by Aromatase Inhibitor in Postmenopausal Women with Hormone Receptor Positive Breast Cancer | To determine the effectiveness of a drug vs. a placebo for 5 years in patients who have completed 5 years of hormone therapy in postmenopausal women with hormone receptor positive breast cancer | Principal Investigator: Rebecca C. Yang, MD For more information contact Kori D. Hesse, study coordinator, at (781) 744-3071 |
| ECOG E5103: A Double Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer | A study of chemotherapy plus a monoclonal antibody or chemotherapy plus a placebo in patients with high risk breast cancer | Principal Investigator: Neela Natarajan, MD For more information contact Kori D. Hesse, study coordinator, at (781) 744-3071 |
| ECOG Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial | To compare hormonal therapy with and without chemotherapy for patients with breast cancer who have an intermediate risk of recurrence | Principal Investigator: Neela Natarajan, MD For more information contact Kori D. Hesse, study coordinator, at (781) 744-3071 |
| S0307: Phase III Trial Of Bisphosphonates As Adjuvant Therapy For Primary Breast Cancer (SWOG) | This study is being done to find out if adding a drug (a bisphosphonate) to hormonal therapy or chemotherapy will help prevent cancer from spreading to the bones or other parts of the body. "Bisphosphonates" are a group of drugs that have strong effects on the bones and have been shown to strengthen the bones in many patients who take them. | Principal Investigator: Corrine Zarwan, MD For more information contact Kori D. Hesse, study coordinator, at (781) 744-3071 |
| ALTTO: ADJUVANT LAPATINIB AND/OR TRASTUZUMAB TREATMENT OPTIMISATION STUDY. A RANDOMISED, MULTI-CENTRE, OPEN-LABEL, PHASE III STUDY OF ADJUVANT LAPATINIB, TRASTUZUMAB, THEIR SEQUENCE AND THEIR COMBINATION IN PATIENTS WITH HER2/ERBB2 POSITIVE PRIMARY BREAST CANCER | This purpose of this research study is to: • Find out what effects (good and bad) the study treatment has on you and your cancer. • Compare four different study treatment combinations to see if one is better • Find out what effects this study has on your quality of life. Because of recent research by NCCTG, the standard treatment for HER2+ breast cancer now includes trastuzumab (Herceptin®). However, not all patients with HER2+ breast cancer do better with trastuzumab, so investigators are trying to find out why. | Principal Investigator: Corrine Zarwan, MD For more information contact Kori D. Hesse, study coordinator, at (781) 744-3071 |
| A RANDOMIZED, MULTICENTER, PHASE III, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF TRASTUZUMAB-MCC-DM1 VS. CAPECITABINE+LAPATINIB IN PATIENTS WITH HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAVE RECEIVED PRIOR TRASTUZUMAB-BASED THERAPY | A RANDOMIZED, MULTICENTER, PHASE III, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF TRASTUZUMAB-MCC-DM1 VS. CAPECITABINE+LAPATINIB IN PATIENTS WITH HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAVE RECEIVED PRIOR TRASTUZUMAB-BASED THERAPY | Principal Investigator: Neela Natarajan, MD For more information contact Kori D. Hesse, study coordinator, at (781) 744-3071 |
| NSABP PROTOCOL B-43: A PHASE III CLINICAL TRIAL COMPARING TRASTUZUMAB GIVEN CONCURRENTLY WITH RADIATION THERAPY AND RADIATION THERAPY ALONE FOR WOMEN WITH HER2-POSITIVE DUCTAL CARCINOMA IN SITU RESECTED BY LUMPECTOMY | This study is being done to compare the effects, good and/or bad, of adding the drug trastuzumab (also called Herceptin®) to breast radiation therapy. Radiation therapy is the standard treatment for patients with DCIS. | Principal Investigator: Stephen E. Karp, MD For more information contact Kori D. Hesse, study coordinator, at (781) 744-3071 |